Where FOXO4-DRI Is Actually Bought
Six routes people try, in the order they usually try them, and what happens at each one.
FOXO4-DRI where to buy is a question most people work through in a predictable order: pharmacy first, then a clinic, then a compounder, then somewhere overseas, then finally a research supplier. Five of those six dead-end, and they dead-end for the same reason each time.
Where the order actually gets placed
Ascension Peptides, FOXO4-DRI
US-based and third-party tested. Enter the code on the payment step and the vial halves before you confirm.
The two published certificates cover different batches and disagree on net content: Kovera Labs assayed batch 55-05260628 at 11.41 mg, MZ Biolabs assayed lot 55-01260229 at 8.30 mg, both against a 10 mg label. Endotoxin and sterility screens appear on the Kovera batch only. The vendor spells the product FOX04 with a zero, including in the link. Buying 3, 5 or 10 takes 3%, 5% or 10% off the list price. Free shipping starts at $250.
- Two batch certificates per lot
- Shipping free over $250
- Out the door same day if you order before 2pm CST
Everything here is research material for laboratory use, not for human consumption. FOXO4-DRI is not an approved medicine in any market and has never been tested in a human trial. Affiliate links, so we may earn a commission at no cost to you. Prices last checked September 2, 2026.
The order people try, and where each one stops
Nobody starts at a research-peptide supplier. They arrive there after the others fail, so it is worth walking the sequence.
| Attempt | What happens | Why | | --- | --- | --- | | Ask a doctor | No prescription written | A prescription instructs a pharmacy to supply an approved product. None exists | | Retail pharmacy | Nothing to dispense | No approved FOXO4-DRI in any market | | Telehealth service | Declined | Same reason, plus no prescriber will write for an unapproved compound | | Compounding pharmacy | Declined | Not on any bulk substance list for compounding | | Longevity clinic | Sometimes offered | Any stock is research-grade, or it is a different compound | | Research supplier | Sold, as lab material | The only channel that exists |
One fact repeats down that column: no marketing authorisation from the FDA, the EMA or the MHRA. Approval is what creates a label, an indication, a dose and a supply chain. Without it, none of those exist to be accessed.
What the clinic step actually is
The fifth row is the one that traps people, because the setting looks medical and the presentation is professional.
A clinic advertising a senolytic protocol is using a marketing phrase, not describing a regulatory status. If it offers FOXO4-DRI specifically, the possibilities are narrow: it is sourcing the same research-grade material you could buy directly, it is supplying something else under a loose label, or it is describing something as senolytic that is not.
The tell is what happens when you ask for documentation. A legitimate medical supply chain produces a manufacturer, a lot and a label. A clinic buying research peptides can produce, at best, the same vendor certificate you could download yourself.
Choosing between research suppliers
Since that is the only route, the real decision is which supplier, and price is close to the least useful signal.
What separates them is whether the contents of the vial can be verified. A batch-specific certificate naming the lot stamped on your vial, from a laboratory with a real name and address. Purity by HPLC and identity by mass spectrometry, because purity alone does not confirm the molecule. A stated net content figure, which is a different measurement from purity and the one almost nobody publishes. Domestic dispatch, so customs is not in the path.
A vial well below market price with no lot number and no named laboratory is not a bargain. It is unidentified powder at a discount.
What the published certificates show
Two laboratories have certified this product on two different batches, and they disagree about how much peptide is in the vial.
| | Kovera Labs | MZ Biolabs | | --- | --- | --- | | Batch | 55-05260628 | 55-01260229 | | Date | Certified 15 June 2026 | Analysed 10 January 2026 | | Purity | 99.411% | 99.97% | | Net content, 10 mg label | 11.41 mg | 8.30 mg | | Endotoxin screen | Pass | Not performed | | Sterility screen | No growth | Not performed |
One batch came in 14% over the labelled mass, the other 17% under, and both purity figures were excellent. Purity and quantity are separate measurements, and quantity is the one that moved.
Testing scope also belongs to the batch rather than the product. The endotoxin and sterility screens exist on the June lot only, so a claim that this product is endotoxin tested is generalising from one certificate. Ask for the one matching the lot you receive.
What no route provides
FOXO4-DRI has never been given to a human being in a registered clinical trial. There is no established dose, no measured half-life in people, and no safety profile. The published evidence is mice, rats and cultured cells, beginning with the 2017 study that reported restored fitness, fur density and renal function in aged mice.
Senolysis is also not uniformly beneficial. A 2023 study found that clearing senescent cells could promote the development and progression of pulmonary hypertension, which is a reminder the effect depends on tissue and context. The same sourcing logic applies across compounds, as set out in the BPC-157 guide and the epithalon guide.